YH 008
Alternative Names: NWY-001; YH-008Latest Information Update: 25 Jan 2024
At a glance
- Originator Beijing Biocytogen
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD40 antigen modulators; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 31 Oct 2023 Chipscreen Biosciences plans phase-I trial for Solid tumours (Late-stage disease) in China (IV) in October 2023 (NCT05979155)
- 09 Aug 2023 Chipscreen Biosciences plans a phase I trial for Solid tumour (Late-stage disease) in China in October 2023 (IV) (NCT05979155)
- 10 May 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in China (Parenteral) (Biocytogen pipeline, May 2023)